C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 58.8% in March

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of “Moderate Buy” by Brokerages

C4 Therapeutics to Participate in Upcoming March Conferences

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Insider Selling: C4 Therapeutics (NASDAQ:CCCC) Insider Sells $22,200.00 in Stock

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

C4 Therapeutics Sees Unusually High Options Volume (NASDAQ:CCCC)

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Brookstone Capital Management Purchases Shares of 29,325 C4 Therapeutics, Inc. $CCCC

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc. - Special Call

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now